Skip to main content
. 2020 Jun 26;22:160. doi: 10.1186/s13075-020-02250-8

Fig. 6.

Fig. 6

PGIA incidence and severity in WT mice after SHP-1 activator administration. Female BALB/c mice were immunized with human PG. Regorafenib was administered daily via oral gavage from the day of the third PG injection. Mice were monitored and scored for symptoms of arthritis 3 times a week. a Arthritis incidence is expressed as the percent of arthritic mice of all animals in each group. b AUC of arthritis incidence. c Arthritis severity is expressed as the mean visual arthritis score ± SEM. d AUC of arthritis severity (n = 5–7/group, **p < 0.01, ***p < 0.001, ****p < 0.0001 vehicle-treated vs 20 mg/kg and Shp1-Tg+/− groups; +++p < 0.001 10 mg/kg vs 20 mg/kg regorafenib; ANOVA followed by Tukey’s multiple comparison). AUCs are shown as box plots (center line, median; box limits, upper and lower quartiles; whiskers, maximum and minimum values)